Loading stock data…
Kura Oncology, Inc. (KURA)
$10.39-0.06 (-0.57%)
Market ClosedLast close Jul 24
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Kura Oncology, Inc. in the Healthcare sector is trading at $10.39 with a market capitalization of $768M. Wall Street consensus targets $31.17 (12 analysts), implying a +200.0% move over the next 12 months. The stock is currently 17% below its 52-week high of $12.49, remaining 7.6% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +200.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $18.27M↑ | $17.34M↓ | $20.75M↑ | $15.29M↑ | $14.11M |
| Gross Profit | $18.00M | — | — | — | $14.11M |
| Operating Income | -$78.81M↑ | -$86.27M↓ | -$80.00M↓ | -$72.67M↓ | -$64.70M |
| Net Income | -$73.33M↑ | -$81.00M↓ | -$74.12M↓ | -$66.12M↓ | -$57.43M |
Peer Comparison
JNJUNHPFE
Fundamentals
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; D...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$768.34M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.32
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-273.05%
Volume
Today's trading volume
1.14M
Recent News
Is Kura Oncology (KURA) Undervalued On New FIT 001 Trial Data?
Kura Oncology (KURA) is back in focus after announcing that updated Phase 1a data from its FIT-001 trial in advanced renal cell carcinoma will be featured in an oral presentation at the 2026 Kidney Cancer Research Summit. See our latest analysis for Kura Oncology. The FIT-001 update comes after a mixed period for Kura Oncology’s stock, with a 1-month share price return of 9.37% and a 90-day share price return of 11.04% contrasting with a 7-day share price decline of 5.15%. The 1-year total...
Does Kura Oncology’s (KURA) Shift Into Russell Growth Indexes Redefine Its Core Investment Story?
Kura Oncology, Inc. was recently added to several Russell growth benchmarks, including the Russell 2000 Growth and Russell 3000 Growth Indexes, while being removed from multiple value benchmarks. This shift from value to growth index classifications may alter how passive and active investors view the company’s risk profile and potential drivers. Next, we’ll examine how Kura’s shift into multiple Russell growth indexes shapes its investment narrative and longer-term positioning. AI is about...
Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates?
We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is one of the most promising stocks on our list. TheFly reported on June 12 that Guggenheim analyst Brad Canino reduced the price target for SNDX to $31 from $34 while maintaining a Buy rating on […]
How The Kura Oncology (KURA) Investment Narrative Is Evolving Without New Analyst Revisions
Kura Oncology’s current analyst price targets remain unchanged, with no revisions in either direction. While there is no new analyst commentary to unpack this time, the lack of adjustments itself can still matter for how you think about risk and reward. In the sections that follow, you will see how to track these kinds of quiet periods in the data so you can stay on top of the evolving narrative around this stock. Wall Street's queuing for one rocket. While SpaceX counts down to its IPO,...
Some Analysts Just Cut Their Kura Oncology, Inc. (NASDAQ:KURA) Estimates
One thing we could say about the analysts on Kura Oncology, Inc. ( NASDAQ:KURA ) - they aren't optimistic, having just...